The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI).
 
Mario Campone
Honoraria - Menarini; Novartis; Servier
Consulting or Advisory Role - Menarini; Novartis; SERVIER
Speakers' Bureau - Amgen; Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Luca Gianni
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; Genomic Health; GlaxoSmithKline; Merck Sharp & Dohme; Pfizer; Roche; Sanofi; Synaffix; Synthon; Taiho Pharmaceutical; Tiziana Life Sciences
Patents, Royalties, Other Intellectual Property - Roche
 
Javier Cortes
Employment - MedSIR
Stock and Other Ownership Interests - MedSIR
Honoraria - Celgene; Eisai; Novartis; Roche/Genentech
Consulting or Advisory Role - Celgene; Roche/Genentech
 
Thaddeus Beck
No Relationships to Disclose
 
Julieann Miller
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Peng Chen
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Abderrahim Fandi
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Jasgit C. Sachdev
Honoraria - Celgene
Consulting or Advisory Role - Celgene